Loading clinical trials...
Loading clinical trials...
An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]
Conditions
Interventions
GW679769 (Casopitant) oral tablets
Rifampin oral capsules
Locations
1
United States
GSK Investigational Site
Tacoma, Washington, United States
Start Date
November 11, 2006
Primary Completion Date
January 5, 2007
Completion Date
January 5, 2007
Last Updated
September 12, 2017
NCT06593782
NCT00404274
NCT00511823
NCT00366834
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions